Sirnaomics, Inc.

Other

Sirnaomics Medicine Technology (suzhou) Co, Ltd.

Vera Simonenko

Patrick Y Lu

John Xu

David R Evans

Qingfeng Li

Ling Li

David M Evans

Yibin Cai

Alan Lu

Deling Wang

Xueping Chen

Danny Tang

Jia Zhou

Compositions and methods for development of potent siRNA therapeutics for prevention and treatment of Corona Virus (2019-nCoV; COVID-19) infections are provided. The compositions include a pharmaceutical composition comprising siRNA cocktails that target critical viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Administration methods for prevention and treatment are provided, including airway instillation, subcutaneous injections and nebulizer aerosolization.

Composition and methods of RNAi prophylactics and therapeutics for treatment of severe acute respiratory infection caused by 2019 novel coronavirus (2019-nCoV)

The current invention provides a method of activating fibroblast and myofibroblast apoptosis in a tissue of a mammal, comprising administering to the tissue a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGFB1 protein in a mammalian cell, an siRNA molecule that binds to an mRNA that codes for COX-2 protein in a mammalian cell, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable histidine-lysine polymer. The invention also provides additional methods for using this composition.

Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis

The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoV) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.

Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection

The present invention provides small interfering RNA (siRNA) molecules, compositions containing them, and methods of using them for improvement of skin scarless wound healing and other skin conditions, such as psoriasis and lupus-caused cutaneous lesions. The invention includes siRNA molecules and compositions containing them that inhibit the expression of one or more genes that promote pathological or undesired processes in wound healing and methods of using them.

Multi-targeted RNAi therapeutics for scarless wound healing of skin

The present invention provides compositions and methods for using combinations of TGF&#x3b2;1 and Cox-2 inhibitors and TGF&#x3b2;1 and Hoxb13 inhibitors for the treatment of various medical conditions, including skin scaring due to trauma wounds and surgery, corneal and retina scaring due to injury and surgery, internal organ scaring due to injury and surgery, heart tissue scaring due to heart attack and surgery, and lung, liver, and kidney fibrosis due to inflammation and injury. One example is to use siRNA inhibitors to silence TGF&#x3b2;1 and Cox-2 at the same time, resulting in significant less scar formation.

Combinations of TGF&#x3b2; and COX-2 inhibitors and methods for their therapeutic application

Growing community of inventors

Germantown, MD, United States of America

Vera Simonenko